TOKYO and RIDGEFIELD, Conn., Nov. 8 Astellas Pharma Inc.and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of BoehringerIngelheim Corporation) announced today that the two companies have reached asettlement agreement with Ranbaxy to enter into a stipulation of dismissal ofthe pending U.S. litigation with regard to U.S. Patent No. 4,703,063 forFlomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs andsymptoms of benign prostatic hyperplasia (BPH).
As a result of this settlement, the case will be dismissed withoutprejudice. The settlement of the litigation provides Ranbaxy with theopportunity to launch a generic tamsulosin hydrochloride product on March 2,2010, prior to the expiration of pediatric exclusivity if such is granted bythe FDA. Further terms of the settlement will not be disclosed.For more information, please contact: Kate O'Connor, Communications & Public Relations Boehringer Ingelheim Pharmaceuticals, Inc. Tel: 203-791-6250 Mobile: 917-446-7400 Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.